News Feed Item

Eisai to Collaborate with Liverpool School of Tropical Medicine and University of Liverpool to Discover New Drugs Against Filariasis

HATFIELD, England, March 20, 2014 /PRNewswire/ --

Joint research project awarded a Global Health Innovative Technology Fund grant

Eisai announced today that it has entered a collaboration with the Liverpool School of Tropical Medicine (LSTM) and the University of Liverpool (UoL) to identify new drugs that are effective against lymphatic filariasis and onchocerciasis (river blindness), both major types of the parasitic tropical disease filariasis.  

Under the collaboration, Eisai will work with the nonprofit LSTM to develop and implement new tools and technologies for the control and treatment of tropical diseases, and with UoL, a world-class institute that has made major contributions toward understanding the mechanisms of drug action of several classes of anti-parasitic drugs, to identify and develop novel drug candidates that efficiently eliminate the bacteria Wolbachia.  Wolbachia live inside the parasitic worms, known as filariae, which cause lymphatic filariasis and onchocerciasis. These two filarial infectious diseases affect more than 150 million people worldwide.[1] As filariae are dependent on Wolbachia bacteria for growth, development, reproduction and survival, the worms can be effectively eradicated by first eliminating the Wolbachia inside them.

While current anti-filarial treatments are effective against larvae and microfilariae, they require many years of consistent, annual mass drug administration in endemic communities to successfully eliminate the adult worms. Anti-Wolbachia therapy is expected to lead to worm sterility and effective worm eradication, thereby reducing treatment times and improving therapeutic outcomes compared to existing anti-filarial drugs. Furthermore, as anti-Wolbachia programmes are still in their infancy, this collaboration has the potential to provide a unique opportunity to make a significant contribution to communities affected by filariasis.

To date, the screening of more than 10,000 potential anti-Wolbachia compounds has revealed approximately 50 potentially promising compounds, leading to identification of about six chemotypes with anti-infective potential. Eisai and its collaboration partners will focus on two of these with the aim of identifying a single candidate for potential drug development within one to two years.

This unique approach has been awarded a two-year grant by the Global Health Innovative Technology Fund (GHIT Fund), an international non-profit organisation that aims to promote the discovery of new health technologies for eliminating infectious diseases prevalent in developing countries.

In support of the World Health Organisation (WHO)'s programme to eliminate lymphatic filariasis by 2020, Eisai is supplying diethylcarbamazine (DEC) free of charge to the WHO. Under its collaboration with LSTM and UoL, Eisai aims to make new treatments available as early as possible to help patients with filariasis and thereby increase further the healthcare benefits provided to these patients and their families in developing and emerging countries.

Notes  to  editors

About  Anti-Wolbachia  Therapy 

Anti-Wolbachia therapy is a new method of treatment that eradicates the adult worms that can cause filariasis by eliminating bacteria known as Wolbachia that live in the cells of their bodies. This approach has the potential to significantly reduce the timescale of elimination programs, to provide alternatives to existing treatments, and to deliver tools that can be used in areas where current approaches are failing or cannot be deployed. Doxycycline, an antibiotic, is believed to work in this way and proof of concept has already been established in human field trials, which showed excellent results although requiring four to six weeks of daily treatment and being unsuitable for administration to children and pregnant women.

Under its collaboration with the Liverpool School of Tropical Medicine (LSTM) and University of Liverpool (UoL), Eisai will aim to identify potential new drug compounds that act more quickly and more effectively than doxycycline and that could be used across all population groups, and to develop these molecules to the stage of pre-clinical safety testing.

About Liverpool School of Tropical Medicine and the University of Liverpool

The LSTM is a non-profit charitable institution with a mission to develop and implement new tools and technologies for the control and treatment of tropical diseases. LSTM has an existing anti-Wolbachia program funded by the Bill and Melinda Gates Foundation and has developed assays and models to test compounds for anti-Wolbachia activity on a large scale.

The Department of Chemistry at the UoL has made major contributions toward understanding the mechanisms of drug action of several classes of anti-parasitic drugs. Over their 20 years in partnership, UoL and LSTM have adopted a "molecule to man" strategy to instigating its research projects, operating at all stages of the drug discovery pipeline up to and including clinical trials in humans. To date, a total of three projects have contributed to the portfolio of the Medicines for Malaria Venture (MMV), an organization that has developed the largest portfolio of anti-malarial drugs in history.

About  the  Global  Health  Innovative  Technology  Fund 

The Global Health Innovative Technology Fund (GHIT Fund) is an international non-profit organization aimed at advancing the research and development of new health technologies from Japan to fight infectious diseases prevalent specifically in the developing world, including HIV/AIDS, malaria, tuberculosis, and neglected tropical diseases (NTDs). Established as a public-private partnership between the Government of Japan, a consortium of pharmaceutical companies, and the Bill & Melinda Gates Foundation, the GHIT Fund facilitates and funds research and development of new health technologies through partnership creation and grant-making activities. For further information, please visit: http://www.ghitfund.org.

About  Eisai 

Eisai is one of the world's leading research and development (R&D) based pharmaceutical companies and we define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call human health care (hhc).

Eisai concentrates its R&D activities in three key areas:

  • Neuroscience, including: Alzheimer's disease, epilepsy, pain and weight loss
  • Oncology including: anticancer therapies; tumour regression, tumour suppression, antibodies, etc.
  • Vascular/Immunological reaction including: thrombocytopenia, rheumatoid arthritis, psoriasis, inflammatory bowel disease

With operations in the U.S., Asia, Europe and its domestic home market of Japan, Eisai employs more than 10,000 people worldwide. From its EMEA Knowledge Centre in Hatfield, UK, Eisai has recently expanded its business operations to include Europe, the Middle East, Africa, Russia and Oceania (EMEA). Eisai EMEA has sales and marketing operations in over 20 markets, including the United Kingdom, France, Germany, Italy, Spain, Switzerland, Sweden, Ireland, Austria, Denmark, Finland, Norway, Portugal, Czech Republic, Slovakia, the Netherlands, Belgium, Russia and the Middle East.

For further information please visit our web site http://www.eisai.co.uk


1.  Filaria-EU  2014  http://www.filaria.eu/fil/fil.html   

Date of preparation: March 2014
Job code: corporate-UK2026

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
@ThingsExpo has been named the Top 5 Most Influential Internet of Things Brand by Onalytica in the ‘The Internet of Things Landscape 2015: Top 100 Individuals and Brands.' Onalytica analyzed Twitter conversations around the #IoT debate to uncover the most influential brands and individuals driving the conversation. Onalytica captured data from 56,224 users. The PageRank based methodology they use to extract influencers on a particular topic (tweets mentioning #InternetofThings or #IoT in this ...
SYS-CON Events announced today that Niagara Networks will exhibit at the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Niagara Networks offers the highest port-density systems, and the most complete Next-Generation Network Visibility systems including Network Packet Brokers, Bypass Switches, and Network TAPs.
In an era of historic innovation fueled by unprecedented access to data and technology, the low cost and risk of entering new markets has leveled the playing field for business. Today, any ambitious innovator can easily introduce a new application or product that can reinvent business models and transform the client experience. In their Day 2 Keynote at 19th Cloud Expo, Mercer Rowe, IBM Vice President of Strategic Alliances, and Raejeanne Skillern, Intel Vice President of Data Center Group and ...
Data is the fuel that drives the machine learning algorithmic engines and ultimately provides the business value. In his session at Cloud Expo, Ed Featherston, a director and senior enterprise architect at Collaborative Consulting, will discuss the key considerations around quality, volume, timeliness, and pedigree that must be dealt with in order to properly fuel that engine.
SYS-CON Events announced today that Cemware will exhibit at the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Use MATLAB functions by just visiting website mathfreeon.com. MATLAB compatible, freely usable, online platform services. As of October 2016, 80,000 users from 180 countries are enjoying our platform service.
Traditional on-premises data centers have long been the domain of modern data platforms like Apache Hadoop, meaning companies who build their business on public cloud were challenged to run Big Data processing and analytics at scale. But recent advancements in Hadoop performance, security, and most importantly cloud-native integrations, are giving organizations the ability to truly gain value from all their data. In his session at 19th Cloud Expo, David Tishgart, Director of Product Marketing ...
SYS-CON Events announced today that StarNet Communications will exhibit at the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. StarNet Communications’ FastX is the industry first cloud-based remote X Windows emulator. Using standard Web browsers (FireFox, Chrome, Safari, etc.) users from around the world gain highly secure access to applications and data hosted on Linux-based servers in a central data center. ...
Virgil consists of an open-source encryption library, which implements Cryptographic Message Syntax (CMS) and Elliptic Curve Integrated Encryption Scheme (ECIES) (including RSA schema), a Key Management API, and a cloud-based Key Management Service (Virgil Keys). The Virgil Keys Service consists of a public key service and a private key escrow service. 

SYS-CON Events announced today that eCube Systems, the leading provider of modern development tools and best practices for Continuous Integration on OpenVMS, will exhibit at SYS-CON's @DevOpsSummit at Cloud Expo New York, which will take place on June 7-9, 2016, at the Javits Center in New York City, NY. eCube Systems offers a family of middleware products and development tools that maximize return on technology investment by leveraging existing technical equity to meet evolving business needs. ...
Effectively SMBs and government programs must address compounded regulatory compliance requirements. The most recent are Controlled Unclassified Information and the EU’s GDPR have Board Level implications. Managing sensitive data protection will likely result in acquisition criteria, demonstration requests and new requirements. Developers, as part of the pre-planning process and the associated supply chain, could benefit from updating their code libraries and design by incorporating changes.
The best way to leverage your Cloud Expo presence as a sponsor and exhibitor is to plan your news announcements around our events. The press covering Cloud Expo and @ThingsExpo will have access to these releases and will amplify your news announcements. More than two dozen Cloud companies either set deals at our shows or have announced their mergers and acquisitions at Cloud Expo. Product announcements during our show provide your company with the most reach through our targeted audiences.
Fact is, enterprises have significant legacy voice infrastructure that’s costly to replace with pure IP solutions. How can we bring this analog infrastructure into our shiny new cloud applications? There are proven methods to bind both legacy voice applications and traditional PSTN audio into cloud-based applications and services at a carrier scale. Some of the most successful implementations leverage WebRTC, WebSockets, SIP and other open source technologies. In his session at @ThingsExpo, Da...
SYS-CON Events announced today that Isomorphic Software will exhibit at DevOps Summit at 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Isomorphic Software provides the SmartClient HTML5/AJAX platform, the most advanced technology for building rich, cutting-edge enterprise web applications for desktop and mobile. SmartClient combines the productivity and performance of traditional desktop software with the simp...
Fifty billion connected devices and still no winning protocols standards. HTTP, WebSockets, MQTT, and CoAP seem to be leading in the IoT protocol race at the moment but many more protocols are getting introduced on a regular basis. Each protocol has its pros and cons depending on the nature of the communications. Does there really need to be only one protocol to rule them all? Of course not. In his session at @ThingsExpo, Chris Matthieu, co-founder and CTO of Octoblu, walk you through how Oct...
SYS-CON Events announced today that Embotics, the cloud automation company, will exhibit at the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Embotics is the cloud automation company for IT organizations and service providers that need to improve provisioning or enable self-service capabilities. With a relentless focus on delivering a premier user experience and unmatched customer support, Embotics is the fas...